Best clinical practice with ziprasidone IM: Update after 2 years of experience

CNS Spectrums

Volumn 10, Issue 9, 2005, Pages 1-15

  Zimbroff, Dan L ^m   Allen, Michael H ^a,b   Battaglia, John ^c   Citrome, Leslie ^d,e   Fishkind, Avrim ^f   Francis, Andrew ^g   Herr, Daniel L ^h   Hughes, Douglas ⁱ   Martel, Marc ^j   Preval, Horacio ^g,k   Ross, Ruth ^l  

^a Psychiatric Emergency Services

^b UNIVERSITY OF COLORADO   (United States)

^c Mendota Mental Health Institute   (United States)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Neuropsychiatric Center   (United States)

^g STONY BROOK UNIVERSITY   (United States)

^h WASHINGTON HOSPITAL CENTER   (United States)

ⁱ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j HENNEPIN COUNTY MEDICAL CENTER   (United States)

^k Comprehensive Psychiatric Emergency Program ^*  (United States)

^l Ross Editorial   (United States)

^m Pacific Clinical Research Medical Group   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE OXIDASE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CYTOCHROME P450 3A4; DEXMEDETOMIDINE; DROPERIDOL; HALOPERIDOL; KETOCONAZOLE; LORAZEPAM; NEUROLEPTIC AGENT; PROPOFOL; PSYCHOTROPIC AGENT; ZIPRASIDONE;

AGITATION; ALCOHOL ABUSE; ANXIETY DISORDER; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DELIRIUM; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; EMERGENCY WARD; EXTRACORPOREAL CIRCULATION; FOOD AND DRUG ADMINISTRATION; HEAD INJURY; HEADACHE; HOSTILITY; HUMAN; HYPERTENSION; INJECTION PAIN; INSOMNIA; INTENSIVE CARE UNIT; MOTOR DYSFUNCTION; ORTHOSTATIC HYPOTENSION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; SUBSTANCE ABUSE; TACHYCARDIA; VENTILATOR; VOMITING;

EID: 26644439946     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900025487     Document Type: Review

References (61)

1. Allen MH, Currier GW. Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry. 2004;26:42-49.
2. Fisher WA. Restraint and seclusion: A review of the litetature. Am J Psychiatry. 1994;151:1584-1591.
3. Sundram CJ, Stack EW, Benjamin WP. Restraint and Seclusion Practices in New York State Psychiatric Facilities. Albany, NY: New York State Commission on Quality of Care for the Mentally Disabled; 1994.
4. Currier GW, Allen MH. American Association for Emergency Psychiatry survey, I: Psychiatric Emergency Service Structure and Function. Presented at: the 51st American Psychiatric Association Institute on Psychiatric Services; October 29-November 2, 1999; New Orleans, LA.
5. Medical Directors Council of the National Association of State Mental Health Program Directors. Reducing the Use of Seclusion and Restraint; Findings. Strategies, and Recommendations. Alexandria, VA: National Association of State Mental Health Program Directors; 1999.
6. Altimari D, Blint DF, Weiss EM, et al. Deadly restraint. Hartford Courant. October 1998. Summary available at: http://www.nami.org/update/990324. html.
7. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. Expert Consensus Panel for Behavioral Emergencies. The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med. 2001;(spec no):1-88.
8. Allen MH, Carpenter D, Sheets JL, et al. What do consumers say they want and need during a psychiatric emergency? J Psychiatr Pract. 2003;9:39-58.
9. National Collaborating Centre for Mental Health, National Institute for Clinical Excellence (NICE). Schizophrenia: Full National Clinical Guideline on Core Interventions in Primary and Secondary Care. London, England: The Royal College of Psychiatrists: Gaskell Books; 2003.
10. Casey DE. Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr Scand Suppl. 1994;89(suppl 380):14-20.
11. King DJ, Burke M, Lucas RA. Antipsychotic drug-induced dysphotia. Br J Psychiatry. 1995;167:480-482.
12. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158(11):1774-1782.
13. Hassaballa HA, Balk RA. Torsade de pointes associated with the administration of intravenous haloperidol: A review of the literature and practical guidelines for use. Expert Opin Drug Saf. 2003;2:543-547.
14. Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry. 2000;61(suppl 14):11-20.
15. Battaglia J. Pharmacological management of acute agitation. Drugs. 2005;65:1207-1222.
16. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med. 1997;15:335-340.
17. Awad AG, Voruganti LNP, Heslegrave RJ. Assessment of the patient's subjective experiences in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol2E 1996;11(Suppl 2):55-60.
18. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 2000;43:135-145.
19. Geodon (ziprasidone mesylate) for Injection. [Package insert]. New York, NY: Pfizer, Inc: August, 2004.
20. FDA Psychophatmacological Drugs Advisory Committee. Briefing document for ziprasidone mesylate for intramuscular injection. February 15, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3685b2_01_pfizer.pdf. accessed January 24, 2005.
21. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001;62:12-18.
22. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial. Psychophamacology (Berl). 2001;155:128-134.
23. Preskorn SH. Pharmacokinetics and therapeutics of intramuscular ziprasidone. Clin Pharmacokinetics. 2005. In press.
24. Swift RH, Harrigan EP, Cappelleri JC, et al. Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients. J Psychiatr Res. 2002;36:87-95.
25. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry. 2000;61:933-941.
26. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24:97-99.
27. Brook S, Walden J, Benattia I, Siu CO, Romano SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl). 2005;178:514-523.
28. Daniel D, Zimbroff DL, Swift RH, Harrigan EP. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol. 2004;19:9-15.
29. Cirrome L, Brook S, Loebel A, Mandel FS, Weissman A. Ziprasidone versus haloperidol for the treatment of agitation. Neuropsychopharmacology. 2004;29(Suppl 1):S111.
30. Gueorgguieva R, Krystal JH. Move over ANOVA. Arch Gen Psychiatry. 2004;61:310-317.
31. Rabinowitz J, Avnon M, Rosenberg V. Effect of clozapine on physical and verbal aggression. Schizophr Res. 1996;22(3):249-255.
32. Volavka J, Citrome L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr Res. 1999;35(Suppl):S23-33.
33. Schillerstrom TL, Schillerstrom JE, Taylor SE. Laboratory findings in emergently medicated psychiatry patients. Gen Hosp Psychiatry. 2004;26:411-414.
34. Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol. 2003;23:229-232.
35. Prakash C, Kamel A, Cui D, et al. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol. 2000;49(suppl 1):35S-42S.
36. Miceli JJ, Anziano RJ, Robarge L, et al. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):65S-70S.
37. Miceli JJ, Smith M, Robarge L, Morse T, Laurent A. The effects of ketoconazole on ziprasidone pharmacokinetics - a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol. 2000b;49(suppl 1):71S-76S.
38. Daniel D, Brook S, Benattia I. Efficacy of intramuscular ziprasidone without adjunctive benzodiazepines. Poster presented at: the 10th Congress of the European College of Neuropsychopharmacology; September 20-24, 2003; Prague, Czech Republic.
39. ZYPREXA® Olanzapine Tablets, ZYPREXA® ZYDIS® Olanzapine Orally Disintegrating Tablets, ZYPREXA® IntraMuscular Olanzapine for Injection {Package Insert], Indianapolis, IN; Eli Lilly and Company; 2005. Available at: www.ZYPREXA.com. Accessed July 13, 2005.
40. Miceli JJ, Anziano MS, Swift RH, et al. IM ziprasidone and IM haloperidol show comparable QTc effects at Cmax. Poster presented at: 156th Annual Meeting of the American Psychiatric Assciation; May 17-22, 2003; San Francisco, CA.
41. Shale JH, Shale CM, Mastin WD. A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. J Clin Psychiatry. 2003;64(5):500-505.
42. Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics. 2005. In press.
43. FDA Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox® capsules (Ziprasidone HCl). July 19, 2000. Available at: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619bla.pdf Accessed January 24, 2005.
44. Freeman J, Platt R. Erythromycin prolongs the QTc interval among patients with pneumonia. Pharmacoepidemiol Drug Saf. 1997;6:13-19.
45. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24(1):62-69.
46. Burton S, Heslop K, Harrison K, Barnes M. Ziprasidone overdose. Am J Psychiatry. 2000;157:835.
47. House M, Overdose of ziprasidone. Am J Psychiatry. 2002;159:1061-1062.
48. Bryant SM, Zilberstein J, Cumpston KL, Magdziarz DD, Costerisan DD. A case series of ziprasidone overdoses. Vet Hum Toxicol. 2003;45:81-82.
49. Preval H, Klotz SG, Southard R, Francis A. Rapid-acting IM ziprasidone in the psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry. 2005;27;140-144.
50. Hick JL, Smith SW, Lynch MT. Metabolic acidosis in restraint-associated cardiac arrest: a case series. Acad Emerg Med. 1999;6(3):239-243.
51. Miner JR, McCoy C. Use of a standardized sedation scale in intoxicated patients in the emergency department. Acad Emerg Med. 2002;9:536.
52. Miner JR, McCoy C, Bitos MA. Standardized intoxication scale vs breath ethanol level as a predictor of observation time in the emergency department. Academic Emer Med. 2003;10:520.
53. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004a;291:1753-1762.
54. Milbrandt EB, Deppen S, Harrison PL, et al. Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 2004;32(4):955-962.
55. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30:119-141.
56. Ely EW, Stephens RK, Jackson JC, et al. Current opinions regarding the importance, diagnosis, and management of delirium in the intensive care unit: a survey of 912 healthcare professionals. Crit Care Med. 2004b;32:106-112.
57. Data on file. Pfizer Inc; New York, NY.
58. Keck PE Jr, Versiani M, Porkin S, West SA, Giller E, Ice K. Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160:741-748.
59. Russell JM, Mackel JA, Leaderer MC. Economic model of IM ziprasidone and haloperidol in acute agitation. Poster presented at: the American Psychiatric Association 55th Institute on Psychiatric Services; October 29-November 2, 2003; Boston, Massachusetts.
60. Ely EW, Truman B, Shintani A. et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA 2003;289(22):2983-2991.
61. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001;29:1370-1379.